Trials / Completed
CompletedNCT00675688
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
A Double-Blind, Randomized, Placebo- and Active-Controlled Safety and Efficacy Study of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 3,544 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bazedoxifene/Conjugate Estrogens (CE) | |
| DRUG | Raloxifene | |
| DRUG | Placebo |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2008-05-12
- Last updated
- 2008-05-12
Source: ClinicalTrials.gov record NCT00675688. Inclusion in this directory is not an endorsement.